Management of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
|
|
- Amberlynn Joseph
- 6 years ago
- Views:
Transcription
1 Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
2 Speaker Disclosure Dr. Blevins has disclosed that he has received grant support and is on the speaker s bureau for AstraZeneca, Boehringer Ingelheim, Lilly and Sanofi, and he is on the advisory committee for Medtronic and Senseonics.
3 Learning Objectives By the end of this activity, the participant will be better able to: Review FDA requirements for new drugs for type 2 diabetes to establish CV safety. Describe the results of cardiovascular outcomes trials with incretin modulators such as DPP4 inhibitors and GLP1 receptor agonists. Describe the results and clinical implications of cardiovascular outcomes trials with SGLT2 inhibitors. Discuss the FDA indication related to cardiovascular benefits of glucose lowering medications. Review the updates to the American Diabetes Association treatment recommendations relating to the effect on CV outcomes of medications for treating type 2 diabetes. Implement the clinical application of the results of cardiovascular outcomes trials in treating patients with type 2 diabetes.
4
5 Timeline of Major Diabetes Outcomes Trials FDA CVOT Guidance 2008 Blue = Intensive vs standard control using same set of glucose-lowering agent(s) Purple = Intensive control with a specific agent vs standard care Red = Placebo- or active-controlled study * = FDA-mandated cardiovascular safety trial ACCORD, Action to Control Cardiovascular Risk in Diabetes; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation; CANVAS, Canagliflozin Cardiovascular Assessment Study; DCCT, Diabetes Control and Complications Trial; DEVOTE, Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events; EXAMINE, Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care; ELIXA, Evaluation of Lixisenatide in Acute Coronary Syndrome; EMPA-REG, EMPA-REG OUTCOME trial; Exenatide Study of Cardiovascular Event Lowering; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; ORIGIN, Outcome Reduction with an Initial Glargine Intervention; PROActive, Prospective Pioglitazone Clinical Trial in Macrovascular Events; RECORD, Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes; SAVOR-TIMI, Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Thrombolysis in Myocardial Infarction; STOP-NIDDM, Study to Prevent Non-Insulin-Dependent Diabetes Mellitus; SUSTAIN, Trial to Evaluate Cardiovascular and Other Long-Term Outcomes with Semaglutide in Subjects with Type 2 Diabetes; TECOS, Trial Evaluating Cardiovascular Outcomes with Sitagliptin; UKPDS, United Kingdom Prospective Diabetes Study; VADT, Veterans Affairs Diabetes Trial. 5
6 Cardiovascular Outcomes Trials: A Brief History 2008 FDA guidance mandating assessment of CV safety of all antihyperglycemic agents in RCTs Designed as noninferiority studies to demonstrate study drug was not associated with more MACE than placebo Some study designs tested for superiority if noninferiority criteria were met Primary endpoint: Composite of cardiovascular death, nonfatal MI, and nonfatal stroke Some primary endpoints included additional components MACE = major adverse cardiovascular events; RCTs, randomized controlled trials. FDA. Guidance for industry: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 6
7 7
8 Case #1 ARS Question 53 y/o female with Type 2 Diabetes x 6 years A1c is 7.2% on metformin and DPP4 On ACEi and statin BP is 118/72 LDL is 69 mg/dl Hx of MI 8 years ago What do you do? 1. Double statin to lower LDL further 2. Reduce the ACEi as her BP is too low to perfuse her coronary arteries 3. Discuss SGLT2 and GLP-1 CV risk reduction trials 4. No changes needed since the DPP-4 is cardioprotective
9 5,380 patients with ACS 16,492 patients with CVD or CVD Risk 14,671 patients with Type 2 diabetes and CVD 9
10 10
11 11
12 12
13 13
14 14
15 15
16 Case #2 ARS Question 66 y/o male with Type 2 Diabetes x 14 years A1c is 8.2% on basal and prandial insulin and metformin On BP meds and statin BP is 138/82 LDL is 55 mg/dl Hx of CAB 12 years ago What do you do? 1. Increase BP med 2. Make adjustments to the insulin and suggest another visit in 3-4 months 3. Discuss SGLT2 and GLP-1 CV risk reduction trials
17 7,020 with Type 2 Diabetes and CVD (2:1 empa:placebo 10,142 with Type 2 diabetes and high CV Risk 17
18 Clinical Outcomes with Empagliflozin Study Design N=7020 patients with T2D and CV EMPA-REG OUTCOME Coronary Artery Disease History of MI History of stroke PAD Randomization Empagliflozin: n=4687 Placebo: n=2333 Noninferiority study: prespecified HR margin = 1.3 for primary endpoint Primary endpoint: composite of CV death, nonfatal MI (excluding silent MI), or nonfatal stroke Secondary endpoint: composite of CV death, nonfatal MI (excluding silent MI), nonfatal stroke, and hospitalization for unstable angina Median follow-up: 3.1 years Week 206 A1C, difference from placebo Empagliflozin 10 mg: -0.24% (95% CI, -0.40% to %) Empagliflozin 25 mg: -0.36% (95% CI, -0.51% to %) CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; MI, myocardial infarction. Zinman B, et al. N Engl J Med. 2015;373:
19 19
20 20
21 21
22 23
23 Clinical Outcomes with Empagliflozin EMPA-REG OUTCOME Safety Results Event Pooled Empagliflozin (%) Placebo (%) Any adverse event Serious adverse event Death Any hypoglycemia Severe hypoglycemia Urinary tract infection Male Female Genital infection Male Female Volume depletion Diabetic ketoacidosis 0.1 <0.1 Bone fracture CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; MI, myocardial infarction. Zinman B, et al. N Engl J Med. 2015;373:
24 Empaglifozin Indication Empaglifozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease 25
25
26 Hematocrit over time in patients treated with empagliflozin 10 mg, empagliflozin 25 mg, and placebo. Silvio E. Inzucchi et al. Dia Care 2018;41: by American Diabetes Association
27 Clinical Outcomes with Canagliflozin CANVAS Program Study Design N=10,142 patients with T2D and high CV risk CANVAS: n=4330 CANVAS-R: n=5812 Randomization (across both studies) Canagliflozin: n=5795 Placebo: n=4347 Endpoints Primary endpoint: composite of CV death, nonfatal MI, or nonfatal stroke Secondary endpoints: All-cause death CV death Albuminuria progression Composite of CV death and HF hospitalization CANVAS, Canaglflozin Cardiovascular Assessment Study; CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; MI, myocardial infarction. Neal B, et al. N Engl J Med. 2017;377:
28 29
29 30
30 Adverse Events with Canagliflozin CANVAS Program* Safety Results Event Canagliflozin Placebo P value Events per 1000-patient years All serious adverse events Adverse events leading to discontinuation Diabetic ketoacidosis (adjudicated) Events of interest occurring in significantly more canagliflozin-treated patients Amputation <0.001 Bone fracture (adjudicated) All Low trauma Infection of male genitalia <0.001 Osmotic diuresis <0.001 Volume depletion Mycotic genital infection in women <0.001 *Includes patients from CANVAS and CANVAS-R (N=10,142). CANVAS-only population (n=4330). Neal B, et al. N Engl J Med Jun 12 [epub ahead of print]. 31
31 CVD-REAL Study Study Objectives Primary Compare risk of HHF (Hospitalization for heart failure) in patients with Type 2 diabetes newly initiated on SGLT-2 inhibitors versus other glucose-lowering drugs (GLDs) Secondary Compare risk of all-cause death between the two treatment groups Compare risk of HHF or all-cause death between the two treatment groups Kosiborod M, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucoselowering drugs: The CVD-REAL Study. Circulation May 18.
32
33
34
35 37
36 Case #4 ARS Question 46 y/o male with Type 2 Diabetes x 4 years A1c is 6.2% on basal insulin and metformin On BP meds and statin BP is 128/82 LDL is 65 mg/dl Hx of PAD and femoral artery stent 1 year ago What do you do? 1. Increase BP med 2. No more to do. His A1c, BP, and LDL are at goal 3. Discuss SGLT2 and GLP-1 CV risk reduction trials
37 6,068 patients with recent ACS 9340 patients with T2D and high CV risk 3297 patients with T2D with CVD, CHF, CKD, or age 60 with 1 CV risk factor 14,752 patients with T2D with or without CVD EXSCEL
38 Clinical Outcomes with Lixisenatide ELIXA (Patients with T2D and CVD; N=6068) Hazard ratio (95% CI) P value Primary composite endpoint* 1.02 ( ) 0.81 Secondary composite endpoint 0.97 ( ) 0.63 CV death 0.98 ( ) 0.85 Fatal or nonfatal MI 1.03 ( ) 0.71 Stroke 1.12 ( ) 0.54 Unstable angina 1.11 ( ) 0.81 Hospitalization for heart failure 0.96 ( ) 0.75 Death from any cause 0.94 ( ) Favors lixisenatide *CV death, nonfatal MI, or nonfatal stroke, and hospitalization for unstable angina; CV death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina, hospitalization for HF, and coronary revascularization. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; MI, myocardial infarction. Pfeffer MA, et al. N Engl J Med. 2015;373:
39 Study Design Clinical Outcomes with Liraglutide LEADER N=9340 patients with T2D and high CV risk Liraglutide Age of >50 History of MI Prior MI or TIA Prior revascularization >50% stenosis of coronary, carotid or lower extremity arteries Symptomatic CHD Heart failure CKD CVD risk factors (age> 60) Microalbuminuria or proteinuria Htn and LVH Ankle brachial index <0.9 Randomization Liraglutide: n=4672 Placebo: n=4668 Key Results Noninferiority study: Primary endpoint: composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke Secondary endpoint: composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, and hospitalization for unstable angina or HF Median follow-up: 3.5 years Difference from placebo at 36 months A1C: 0.40% (95% CI, 0.45% to 0.34%) Weight: 2.3 kg (95% CI, 2.0 to 2.5 kg) SBP: 1.2 mm Hg (95% CI, 0.5 to 1.9 mm Hg) Lower numerical incidence of pancreatitis in liraglutide group (not statistically significant) CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; MI, myocardial infarction. Marso SP, et al. N Engl J Med. 2016:375:
40 42
41 Clinical Outcomes with Liraglutide LEADER Adverse Events Leading to Discontinuation Event Liraglutide (%) (n=4668) Placebo (%) (n=4672) P value Any adverse event <0.001 Serious adverse event Nausea <0.001 Vomiting 0.7 <0.1 <0.001 Diarrhea <0.001 Increased lipase level Decreased appetite 0.2 < Abdominal discomfort Marso SP, et al. N Engl J Med. 2016:375:
42 Liraglutide Indication Liraglutide is a glucagon like peptide 1 (GLP 1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus To reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease 44
43 Clinical Outcomes with Exenatide EXSCEL Study Design N=14,752 patients with T2D with or without CVD By design, 70% had CVD (n=10,782; 73.1%) Randomization Exenatide: n=7356 Placebo: n=7396 Primary endpoint: composite of CV death, nonfatal MI, or nonfatal stroke Secondary endpoints: all-cause death, CV death, nonfatal or fatal MI, nonfatal or fatal stroke, and hospitalization for acute coronary syndrome or HF Key Results Median follow-up: 3.2 years Difference from placebo at trial end A1C: 0.53% (95% CI, 0.57% to 0.50%; P<0.001) Weight: 1.3 kg (95% CI, 1.4 to 1.1 kg; P<0.001) SBP: 1.6 mm Hg (95% CI, 1.9 to 1.2 mm Hg; P<0.001) No difference between treatment groups in confirmed cases of pancreatitis, pancreatic cancer, or medullary thyroid carcinoma CI, confidence interval; CV, cardiovascular; EXSCEL, Exenatide Study of Cardiovascular Event Lowering; HF, heart failure; HR, hazard ratio; MI, myocardial infarction. Holman RR, et al. N Engl J Med Sept 14 [Epub before print]. 45
44 Clinical Outcomes with Exenatide EXSCE(N=14,752) Holman RR, et al. N Engl J Med Sept 14 [Epub before print]. 46
45 New Antihyperglycaemic Medication Usage Proportion (%) Metformin Sulfonylureas Thiazolidinediones DPP-4i SGLT-2i* GLP-1 Receptor Agonists** Exenatide Placebo Insulin Subjects are considered to have taken a new medication if there is no indication of usage at baseline visit as well as indication of usage during at least one postrandomisation visit. Percentages presented are for available data. * Information regarding SGLT-2 inhibitor usage was added to the ecrf on 9th May, Percentages presented are for ITT population. ** Includes GLP-1 receptor agonist usage other than study medication
46 Clinical Outcomes with Exenatide EXSCEL Serious Adverse Events and Events of Special Interest Event Exenatide (%) (n=7344) Placebo (%) (n=7372) Any serious AE Serious adverse treatment-related event Serious AE leading to study withdrawal Events of Clinical Interest Adjudicated pancreatitis Severe pancreatitis <0.1 <0.1 Adjudicated cancer (any) Adjudicated medullary thyroid carcinoma <0.1 <0.1 Adjudicated pancreatic cancer Severe hypoglycemia Event rate 1.6 per 100 pt-years 1.8 per 100 pt-years AE, adverse event. Holman RR, et al. N Engl J Med Sept 14 [Epub before print]. 48
47 Clinical Outcomes with Semaglutide SUSTAIN 6 Study Design N=3297 patients with T2D with CVD, CHF, CKD, or age 60 with 1 CV risk factor Randomization Semaglutide: n=1648 Placebo: n=1649 Noninferiority study: Primary endpoint: composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke Key secondary endpoints Composite of CV death, nonfatal MI, nonfatal stroke, coronary or peripheral revascularization, and hospitalization for unstable angina or HF Composite of all-cause death, nonfatal MI, nonfatal stroke Retinopathy complications New or worsening nephropathy CI, confidence interval; CHF, congestive heart failure; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; HF, heart failure; HR, hazard ratio; MI, myocardial infarction; SUSTAIN, Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes. Marso SP, et al. N Engl J Med. 2016:375:
48 Composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke 50
49 Clinical Outcomes with Semaglutide SUSTAIN 6 Results (N=3297) Median follow-up: 2.1 years Hazard ratio (95% CI) P value Primary composite endpoint* 0.74 ( ) 0.02 Expanded composite endpoint 0.88 ( ) All-cause death, nonfatal MI, nonfatal stroke 0.77 ( ) 0.03 Death from any cause 1.05 ( ) 0.79 CV death 0.98 ( ) 0.92 Nonfatal MI 0.74 ( ) 0.12 Nonfatal stroke 0.61 ( ) 0.04 Revascularization 0.65 ( ) Retinopathy complications 1.76 ( ) 0.02 New or worsening nephropathy 0.64 ( ) Favors semaglutide *CV death, nonfatal MI (including silent MI), or nonfatal stroke; CV death, nonfatal MI, nonfatal stroke, coronary or peripheral revascularization, and hospitalization for unstable angina or HF. CI, confidence interval; CV, cardiovascular; HF, heart failure; MI, myocardial infarction. Marso SP, et al. N Engl J Med. 2016:375:
50 Clinical Outcomes with Semaglutide SUSTAIN 6 Selected Adverse Events Event Semaglutide 1 mg (%) (n=822) Placebo 1 mg (%) (n=825) Any adverse event Serious adverse event Gastrointestinal disorder Diarrhea Nausea Vomiting Acute pancreatitis Gallbladder disorder Cholelithiasis Acute cholecystitis Severe or symptomatic hypoglycemia Injection site reaction Neoplasm (any) Any malignant Malignant pancreatic Marso SP, et al. N Engl J Med. 2016:375:
51
52
53
54 Baseline Patient Characteristics for CV Risk Reduction Empaglifozin Coronary Artery Disease History of MI History of stroke PAD Liraglutide Age of >50 History of MI Prior MI or TIA Prior revascularization >50% stenosis of coronary, carotid or lower extremity arteries Symptomatic CHD Heart failure CKD CVD risk factors (age> 60) Microalbuminuria or proteinuria Htn and LVH Ankle brachial index <0.9
55 Clinical Guidelines and CVOT AACE ADA
56
57
58
59
60 Cardiovascular Risk Reduction in Diabetes 2018
61
62
63
64
65
66 Case #3 ARS Question 47 y/o female with Type 2 Diabetes x 15 years A1c is 7.8% on metformin + GLP-1 med On ACEi and statin BP is controlled LDL is 60 mg/dl BMI is 32 Hx of coronary stent placed last year What do you do? 1. Add basal insulin 2. Discussed exercise and weight loss 3. Discuss SGLT2 CV risk reduction trials
67 Q and A
68 ARS #1. True/False Before 2O15, there was limited data that showed that glucose lowering medications reduce cardiovascular disease 1. True 2. False
69 ARS #2 The following meds have been shown to reduce cardiovascular events in outcomes trials 1. Sitagliptin 2. Empaglifozin 3. Exenatide 4. Liraglutide 5. 2 and 4
70 ARS #3 Baseline characteristics in the Empaglifozin trial which showed reduction in CV death included the following: 1. Smoking 2. Heart calcium (Agatson) score of > Prior MI 4. Prior stroke 5. 3 and and 3
Cardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationCardiovascular Consequences of Diabetes Mellitus
Cardiovascular Consequences of Diabetes Mellitus William J. Elliott, M.D., Ph.D. 05 MAY 18 Disclosure Statement The speaker s research and educational activities have been supported in the past (but NOT
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More information2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?!
2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?! Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Assistant Professor,
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationDiabetes Drugs and Cardiac Disease. Disclosures
Diabetes Drugs and Cardiac Disease Robert J. Rushakoff, MD Professor of Medicine University of California, San Francisco robert.rushakoff@ucsf.edu Disclosures None 1 Written Comments As I have said every
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationGlucose Lowering Medications and CV Risk Reduction: A New Era Jane EB Reusch MD ADA President for Medicine and Science
Glucose Lowering Medications and CV Risk Reduction: A New Era Jane EB Reusch MD ADA President for Medicine and Science Professor of Medicine, Division of Endocrinology, Metabolism and Diabetes and Associate
More informationNew Therapies for Type 2 Diabetes
New for Type 2 Diabetes Joshua J. Joseph, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical Center Financial Disclosures: None
More informationNew Therapies for Type 2 Diabetes
New for Type 2 Diabetes Joshua J. Joseph, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical Center Financial Disclosures: None
More informationDISCLOSURES. Learning objectives NAVIGATING THE TREATMENT OF TYPE 2 DIABETES: WHAT S NEW? Investigator Initiated Trial Support:
NAVIGATING THE TREATMENT OF TYPE 2 DIABETES: WHAT S NEW? Jane E-B Reusch MD Professor of Medicine, Biochemistry and Bioengineering Associate Director Center for Women s Health Research University of Colorado
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationContent Development Committee
1 Content Development Committee Cardiologists: Family Physicians: Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA, FCCS (Chair) Associate Head, Division of Cardiology, St. Michael s Hospital Professor,
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationReview of FDA Guidance on Cardiovascular Outcomes for Diabetes Medication Trials and Application to Clinical Management
Katherine S. O Neal Pharm.D., MBA, BCACP, CDE, BC-ADM, AE-C Associate Professor The University of Oklahoma Health Sciences Center College of Pharmacy Department of Internal Medicine Oklahoma City, OK Member,
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationDiabetes Management in CAD Patients. Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts
Diabetes Management in CAD Patients Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts Disclosure Stuart R. Chipkin, MD, FACE Nothing to disclose
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationEducational Objectives
Educational Objectives Recognize the rationale for cardiovascular outcome trials (CVOTs) in T2DM and review data from recent CVOTs of anti hyperglycemic agents Examine alignment of managed care T2DM treatment
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationEvaluating the Cardiovascular Benefits of Antidiabetic Medications
Evaluating the Cardiovascular Benefits of Antidiabetic Medications Target Audience: Pharmacists ACPE#: 0202-0000-18-054-L01-P Activity Type: Application-based Disclosures Stuart T. Haines has no relevant
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationWITH SO MANY NEW CLASSES OF MEDICATIONS OUT THERE
UPDATE ON THE NEW DIABETES MEDICATIONS AND HOW TO INCORPORATE INTO YOUR PRACTICE Amy DeGueme, MD, ECNU Madison Medical Affiliates 3/15/19 WITH SO MANY NEW CLASSES OF MEDICATIONS OUT THERE Which ones to
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationCardiovascular Outcome Trials of Diabetes Medications: Translating Results into Practice
Presenter Disclosure Information Cardiovascular Outcome Trials of Diabetes Medications: Translating Results into Practice Carol Hatch Wysham, MD Clinical Professor of Medicine University of Washington
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationFaculty. Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY
Faculty Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY 2 Disclosures Robert S. Busch, MD, FACE serves as a speaker for Astra Zeneca,
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationEmergence of the New Classes of Compounds for Managing Heart Disease in Diabetes Mellitus
Emergence of the New Classes of Compounds for Managing Heart Disease in Diabetes Mellitus Mikhail Kosiborod, MD Professor of Medicine (Cardiology) Saint Luke s Mid America Heart Institute University of
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationKeep Calm and Focus on the Evidence for the Management of Diabetes. Diabetes Update 2018
Keep Calm and Focus on the Evidence for the Management of Diabetes Diabetes Update 2018 Nicole C.Pezzino, PharmD, BCACP, CDE Assistant Professor, Wilkes University Pharmacist, Weis Markets Nicole.pezzino@wilkes.edu
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationClass Update: Sodium glucose Cotransporter 2 (SGLT2) Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTHE EVOLUTION OF CLINICAL TRIALS IN T2DM: FROM TARGETING A1C TO TARGETING CARDIOVASCULAR OUTCOMES
Learning Objectives 1) Evaluate the interrelationship between diabetes, glycemic control, and cardiovascular disease. 2) Examine the evolution of type 2 diabetes (T2DM) drug development and factors leading
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationGLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED
More informationClass Update: Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationStephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital
Stephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital Financial Disclosures Consulting Panel for GSK on Hepatitis Vaccines Case Study BH is a 67 y/o female with T2 DM for
More informationPHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL
Dr Aurora Alcantara Endocrinology PHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL SPED Convention and Diabetes Postgraduate Course May26-29 Wyndham Grand Rio Mar, PR DISCLOSURES Speaker for the following
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationUpdates in Diabetes Care
Updates in Diabetes Care Disclosures Nothing to disclose Pharmacist Objectives 1. List strategies for improving diabetes care 2. Understand benefits and risks associated with newer pharmacotherapeutic
More informationManaging Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University
Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University Objectives: By the end of this session, you will be able to: Identify
More informationCurrent Updates & Challenges In Managing Diabetes in CVD
Current Updates & Challenges In Managing Diabetes in CVD Preventive Cardiovascular Conference 2016 Instituit Jantung Negara 12 th November 2016 Nor Azmi Kamaruddin Diabetes Clinic Department of Medicine
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationSGLT2 Inhibitors Improve CardioRenal Outcomes in DM2-Get Rid of the Sugar
SGLT2 Inhibitors Improve CardioRenal Outcomes in DM2-Get Rid of the Sugar David Balis, MD University of Texas Southwestern Medical Center Internal Medicine Grand Rounds 10/6/17 This is to acknowledge that
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationCanadian Journal of Diabetes
Can J Diabetes 42 (2018) S88 S103 Contents lists available at ScienceDirect Canadian Journal of Diabetes journal homepage: www.canadianjournalofdiabetes.com 2018 Clinical Practice Guidelines Pharmacologic
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationCardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add?
Editorial Page 1 of 5 Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add? Keith C. Ferdinand, Indrajeet Mahata Department of Medicine, Tulane School of Medicine,
More informationDisclaimers 22/03/2018. Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2
Disclaimers Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2 I have not received money or gifts from medical device companies or from the pharmaceutical
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More information